Key Highlights

IscAlert™ is a ground-breaking, patented and proven solution

  • Continuous pCO2 monitoring with accurate real-time readings to prevent ischemia related complications.

  • Potential to help millions of patients, reduce the number of intensive care patients and save many lives.

  • Received funding from the European Union (European Innovation Council), the Norwegian Research Council and Innovation Norway.

CE mark and FDA clearance

  • Our first clinical trial was completed in June 2022 with excellent results.

  • We are presently undergoing the certification process to obtain the CE mark for IscAlert™ in compliance with the Medical Device Regulation (MDR) 2017/745.

  • Additionally, we are preparing to submit a 510(k) application to obtain FDA clearance for IscAlert™.

Untapped global potential for products that detect ischemia

  • Approx. 10 million cases of ischemia in Europe alone.

Multi-talented and highly educated team

  • Management and key employees with track record of achieving CE Mark and FDA approval.

  • 22 employees. Approx. 65% of employees holds a PhD or MSc degree.

Description of the innovation

IscAlert is a patented micro sensor for detection of ischemia, a common consequence of illness, injury and surgery that is suffered by 30 million people and kills >10m people each year globally. Ischemia is a restriction of blood supply to tissues, causing a shortage of oxygen, reduced availability of nutrients and inadequate removal of metabolic wastes, eventually leading to cell death. If detected early, ischemia is highly preventable, however, there is currently no sensor system available for continuous accurate real time detection of ischemia. IscAlert innovatively detects altered pCO2, a key indicator of ischemia, thereby addressing a large and unmet medical need.

Partnerships

Our technology will bring added value to several medical areas. We welcome partnering initiatives from healthcare companies with attractive distribution networks both regionally and globally.

Please contact Sales and Marketing Lead, Jon Sigurd Syvertsen, jon.sigurd@sensocure.no, to explore partnership opportunities.

Investor Relations

Please contact CEO, Trond Herje, for investor related questions.

Email: trond@sensocure.no

Value Proposition for Sensocure AS

 

  • Company Overview: Sensocure AS specializes in developing groundbreaking biomedical sensors for healthcare, including IscAlert™, the world's first implantable microsensor for the early detection of ischemia.

  • Innovation and Technology: IscAlert™ represents a revolutionary advancement in medical technology, providing surgeons and healthcare organizations with a user-friendly, fast, robust, and cost-effective real-time monitoring device for detecting ischemia at its earliest stages.

  • Patient-Centric Approach: Sensocure's mission is driven by the urgent need to address the challenge of late detection of organ injuries. IscAlert™ offers a solution by providing early, accurate, and real-time monitoring, ultimately improving patient outcomes and reducing the risk of preventable ischemic events.

  • Quality and Reliability: Sensocure is committed to delivering high-quality and reliable products like IscAlert™, which directly addresses the critical medical need for real-time monitoring of ischemia, enhancing patient safety and well-being.

  • Ethical and Social Responsibility: Sensocure recognizes the significant impact of early ischemia detection in preventing organ damage and improving patient care. IscAlert™ embodies ethical responsibility by providing a timely and effective solution to a pressing medical challenge.

  • Sustainability and Future Focus: Sensocure is dedicated to ongoing research and development efforts aimed at advancing biomedical sensor technology, with IscAlert™ leading the way in addressing unmet medical needs and shaping the future of healthcare.

  • Competitive Market Engagement: IscAlert™ fills a crucial gap in existing medical solutions by offering real-time monitoring of ischemia, aligning with Sensocure's commitment to providing innovative and effective healthcare solutions in a competitive market landscape.

  • Stakeholder Consideration: Sensocure values its stakeholders' interests and strives to build strong relationships by offering products like IscAlert™, which not only improve patient outcomes but also substantially reduce healthcare costs by minimizing the need for intensive care through early detection and intervention